




REVISTA MÉDICA DEL  
**HOSPITAL GENERAL**  
DE MÉXICO

[www.elsevier.es/hgmx](http://www.elsevier.es/hgmx)



REVIEW ARTICLE

## Advantages of ketamine as a perioperative analgesic



D.M. Rascón-Martínez<sup>a</sup>, O. Carrillo-Torres<sup>b,\*</sup>, R.G. Ramos-Nataren<sup>c</sup>, L. Rendón-Jaramillo<sup>d</sup>

<sup>a</sup> Anaesthesiology Department, UMAE Hospital de Especialidades CMN SIGLO XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>b</sup> Anaesthesiologist and Intensivist Pain Manager at the Anaesthesiology Department of the Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico

<sup>c</sup> Anaesthesiologist at the Anaesthesiology Department, UMAE Hospital de Especialidades CMN SIGLO XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

<sup>d</sup> Anaesthesiology Intern at the Anaesthesiology Department of the Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico

Received 22 August 2016; accepted 18 October 2016

Available online 9 November 2016

### KEYWORDS

Ketamine;  
Analgesia;  
Pain

**Abstract** The pharmacological effects of ketamine are being discovered constantly, and new mechanisms involving epi-genetics could account for some of its clinical responses. Nowadays, it is regarded as a pharmacological tool in translational research and has the potential to revolutionise the therapy of complex patient conditions such as pain and depression.

Medical interest in exploring the drug's properties has grown, as is demonstrated by the increased investigation over the last five years, according to research sites such as Pubmed. These publications draw attention to the multifaceted roles of ketamine as an anaesthetic, analgesic (in multiple contexts, chronic, acute, refractory and breakthrough pain), antihyperalgesic, neuromodulator, bronchodilator and/or antidepressant. It is therefore important to review the pharmacological characteristics and their implications in current treatments.

© 2016 Sociedad Médica del Hospital General de México. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### PALABRAS CLAVE

Ketamina;  
Analgesia;  
Dolor

### Ventajas de la ketamina como analgésico perioperatorio

**Resumen** Los efectos farmacológicos de la ketamina están siendo continuamente descubiertos y nuevos mecanismos que involucran a la epi-genética podrían explicar algunas de sus respuestas clínicas. Hoy día se considera una herramienta farmacológica en la investigación translacional y tiene el potencial de revolucionar la terapéutica de condiciones complejas para el paciente como son el dolor y la depresión.

\* Corresponding author at: Jardín 12 Belisario Domínguez sección XVI, Tlalpan, Mexico City, Mexico. Tel.: +52 5524422026.  
E-mail address: [orlo\\_78@hotmail.com](mailto:orlo_78@hotmail.com) (O. Carrillo-Torres).

El interés médico en conocer las propiedades del fármaco en diferentes contextos ha aumentado y prueba de ello es que en los últimos cinco años, ha habido un aumento significativo en la investigación según sitios como Pubmed. Estas publicaciones, muestran los roles multifacéticos de la ketamina como anestésico, analgésico (en múltiples contextos como dolor agudo, crónico, refractario e irruptivo), antihiperálgico, neuromodulador, broncodilatador y/o antidepresivo. Por ello es importante revisar las características farmacológicas y sus implicaciones en la terapéutica actual.

© 2016 Sociedad Médica del Hospital General de México. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Ketamine is a drug that is becoming increasingly more consolidated in anaesthetic practice. It was synthesised by Calvin Stevens in 1962 and was first used by Domino and Corssen in 1965.<sup>1</sup> It was introduced into Mexico in 1970.

It is an arylcyclohexylamine derivative whose structure is related to phencyclidine and cycloheximide, the main antagonist of N-Methyl-D-Aspartate (NMDA), an excitatory amine, by blocking the receptors of the same name.<sup>2</sup>

The properties of this molecule allow it to act on different levels and thus achieve effects such as sedation, analgesia and anaesthesia; it also has anti-inflammatory, antidepressant and neuroprotective properties.

The purpose of this review is to emphasise its current role, indications, pharmacokinetics, pharmacodynamics and different clinical uses.

## Pharmacological properties

It is a white crystalline, water-soluble salt that is stable at room temperature. It has a molecular weight of 238, with a PK of 7.5.<sup>3</sup>

The ketamine molecule contains a chiral centre that produces two optical isomers, of which the S isomer (+) has a major advantage over the R isomer (–) as its anaesthetic and analgesic properties are four times more potent (Fig. 1).<sup>3,4</sup>

It is marketed in formulated concentrations containing 10, 50 and 100 mg of base ketamine with phemerol or benzethonium chloride as preservative, and the pharmaceutical presentations are slightly acid (pH 3.5–5.5).<sup>5</sup>

Intravenous administration at 2 mg/kg of weight produces unconsciousness after 20–60 s,<sup>5,6</sup> making it the inductor with the fastest onset of action, an advantage which is accounted for by its high Ke0 (0 elimination constant) of 1.3 L/min and its  $t_{1/2}$  (elimination half-life) Ke0 of 0.53 min.<sup>7</sup>

Its bioavailability when given intramuscularly is 93%, yielding plasma concentrations five minutes after administration. Orally, only 17% is available due to the first-pass effect. It binds to proteins at 40–50%, with a volume of distribution of 0.3 ml/kg and a plasma concentration therapeutic window of 0.5–2.5 mcg/ml.<sup>7</sup>

Metabolism takes place in the hepatic microsomal system, when it becomes Norketamine (N-desmethyl ketamine), with a potency of 1/3 to 1/10 with regard to

the initial molecule. Clearance is 18 ml/kg/min, with an elimination  $t_{1/2}$  of 2–3 h.<sup>8</sup>

Intact renal excretion is 4%, and 16% in different forms. It is important to point out that joint administration with benzodiazepines prolongs the elimination half life due to the competitive inhibition of N-desmethyl ketamine.<sup>9</sup>

A suitable analgesic effect may be obtained with levels from 40 ng/ml, which can easily be reached with IV doses of 0.2–0.75 mg/kg or IM of 2–4 mg/kg.<sup>10</sup>

## Mechanism of action

The main central action site is the thalamocortical projection system. It thus selectively depresses neural function, particularly in areas of association and the thalamus, while simultaneously stimulating the limbic system, including the hippocampus, which creates a functional disorganisation of non-specific pathways in the midbrain and the thalamic area. It also depresses the transmission of impulses in the medullary reticular formation, an important structure in the transmission of the emotional affective components of pain perception, from the spinal cord to the higher centres of the brain, thus giving rise to the term ‘‘dissociative anaesthesia’’.<sup>11,12</sup> This function depends on the interaction with the NMDA (N-methyl-D-Aspartate) receptors, which may be blocked by drugs such as phencyclidine and ketamine. There is evidence of opioid receptor occupation in the brain and spinal cord (the S enantiomer acts on the mu receptor), which could account for some of its analgesic effects on the central nervous system (brain and spinal cord).<sup>8,13–15</sup> Therefore, due to the existence of a common receptor, cross tolerance may be expected between opiates and ketamine.<sup>16</sup> This theory would gain greater credence if naloxone reversed its effects in human beings, although Stella et al., in a study with 68 adults premedicated with naloxone for general surgery, found dysphoric reactions to emersion. One possible theory is the stimulation of the sigma opioid receptors.<sup>16,17</sup>

There is also evidence of stimulation of the muscarinic/nicotinic cholinergic receptors, serotonin, dopamine and norepinephrine receptors, type-L calcium channels and sodium channels.<sup>18</sup>

## Pharmacological actions

### Effects on the central nervous system

Ketamine produces a cataleptic condition different from the general anaesthesia produced by other agents that simulates normal sleep.<sup>19</sup>

These patients have profound analgesia, but their eyes remain open and they maintain many reflexes (corneal, tus-sigenic, swallowing), which should not be interpreted as being protective; the pupils dilate moderately and nystagmus appears, there is tearing, salivation and movements of the head and limbs; however, practically none of these effects appears when it is used at sub-anaesthetic doses for the treatment of chronic pain.<sup>19,20</sup>

It increases cerebral metabolism, cerebral blood flow and intracranial pressure (ICP).<sup>21</sup> Pfenninger et al. studied mechanically-ventilated pigs with increased ICP in which the ICP was measured, with no increase found in ICP with doses of 0.5–2.0 mg/kg of the intravenous medicinal product.<sup>22</sup>

It provokes clear changes in the EEG, with a reduction in the activity of alpha waves and with increases in beta, delta and theta waves.<sup>23</sup> It is difficult to draw conclusions on its anticonvulsant properties.<sup>24</sup> Although there is an epilep-tiform EEG pattern in the limbic and thymic regions of human beings, there is no evidence that it affects cortical regions.<sup>23,24</sup>

Psychic phenomena have been reported, such as the sensation of floating, vivid dreams, hallucinations and delirium. These phenomena are more common in patients above the age of 16 years, women, after short procedures, large doses and rapid administration.<sup>25</sup> The benzodiazepines, and more particularly midazolam, have proven to be the most efficacious agents in the prevention of these symptoms. In this regard, clinical studies comparing diazepam and midazolam have been conducted, with the latter having been found to be enormously superior, as well as reducing anaesthetic recovery time in the surgical setting.<sup>26</sup>

### Effects on the cardiovascular system

The capacity to stimulate the cardiovascular system is one of its main outstanding characteristics versus other intravenous

anaesthetic agents.<sup>27</sup> The benzodiazepines can attenuate cardiostimulatory response.

It is the only anaesthetic with sympathomimetic action, which produces stimulation at cardiac level and in the peripheral resistances. An increase in all the haemodynamic constants has been described: heart rhythm, systemic blood pressure, systemic vascular resistances, pulmonary arterial pressure and pulmonary vascular resistances due to an increase in catecholamines caused by re-uptake inhibition.<sup>28</sup>

The acute haemodynamic effects in children were studied by Morray et al. two minutes after the application of 2 mg/kg, with minimum changes found, and independent of intracardiac short circuit, PaCO<sub>2</sub> and PaO<sub>2</sub>. With the same dose, Hickey et al. found no changes in pulmonary vascular resistance, systemic vascular resistance and cardiac index in intubated and mechanically-ventilated infants.<sup>27-29</sup>

### Effects on the respiratory system

During the initial phase after administration, there is a slight depression of respiration (greater in newborns), although permeability of the respiratory tract, skeletal muscle and diaphragm tone are conserved; for this reason, it does not interfere with ventilatory mechanics.<sup>30</sup>

Its bronchodilator reaction, well-known since the first clinical studies, is of particular importance, and it is effective in the prevention of bronchoconstriction caused by circulating catecholamines. The aforementioned reasons make it the drug of choice for the induction of anaesthesia in asthmatic patients.<sup>30</sup>

### Acute post-operative pain

Nowadays, satisfactory post-operative pain control is one of the most important as-yet unresolved challenges in the surgical setting and has a major impact on patients and on the health system in general. Pain is a warning function that triggers protective responses and seeks to minimise tissue damage. When tissue damage is unavoidable, a cascade of changes takes place in the central and peripheral nervous system that is responsible for pain perception.<sup>31</sup>

The reported therapeutic concentrations of ketamine for analgesia are 200 ng/ml, and a suitable analgesic effect is




Figure 1 Ketamine stereoisomers.

obtained with levels starting from 40ng/ml, IV doses of 0.2–0.75 mg/kg or IM doses of 2–4 mg/kg.<sup>32</sup>

Ketamine has proven its effectiveness in the reduction of post-operative pain in several types of surgery (Table 1).

The combination with intrathecal dexmedetomidine delivers superior post-operative analgesia and prolongs analgesic time with a reduction in the total consumption of morphine without greater side effects in comparison with each drug separately.<sup>33</sup>

In combination with local anaesthesia for modified pecs block, it prolongs the time to the first request for analgesia and gives rise to a reduction in total opioid consumption without serious side effects in patients undergoing modified radical mastectomy.<sup>34</sup>

#### **Antidepressant effect**

Ketamine has recently emerged as an effective treatment in refractory depression. Depression is associated with the loss of neurons, a reduction in the number of synapses and dendritic dearborisation. The drug can potently induce mechanisms that reverse these neurodegenerative processes, not only by blocking the glutamate receptor, but also by activating the eukaryotic elongation factor (eEF2). This, in turn, activates the synthesis of proteins derived from the brain-derived neurotrophic factor (BDNF), which appears to provide the foundations for lasting benefits.<sup>35</sup>

#### **Analgesia in burn patients**

Intravenous ketamine has demonstrated its analgesic efficacy in burns, with a reduction in secondary hyperalgesia, in comparison with opioid monotherapy. The combination of ketamine plus morphine resulted in the abolition of hyperalgesia in a study of 67 burn patients.<sup>36</sup>

#### **Opioid-induced anti-hyperalgesic**

Opioid-induced anti-hyperalgesia is related to high doses, prolonged administration or the abrupt interruption of opioid infusion. Ketamine is known to significantly attenuate this condition by means of an intra-operative bolus or infusion<sup>37</sup> due to opioid-induced tolerance and hyperalgesia, there being no totally effective treatment for pain caused by this condition. The mechanism postulated is the activation of the NMDA receptor. Ketamine's antagonistic activity on the NMDA receptor has been shown to regulate opioid-induced hyperalgesia. A review in PubMed showed 4 published articles about ketamine in the management of pain caused by sickle-cell disease with opioid-induced hyperalgesia, which found that the patients that received a ketamine infusion presented a reduction in pain intensity and a significant reduction in opioid doses.<sup>38</sup>

#### **Avoiding opioid dependence and tolerance**

The endogenous opioid peptides (EOP) are strongly related to other systems for the development of tolerance and dependence. These phenomena also involve dopamine and oxytocin, blocking the onset of tolerance versus beta-endorphins and enkephalins. The NMDA block the onset of tolerance through interaction with the mu or delta opioid receptors which are related to this phenomenon. Recent studies suggest that the NMDA and CCKB receptors also

mediate opioid tolerance by means of a convergent nitric oxide pathway as the second messenger.<sup>39</sup>

#### **For the treatment of chronic pain**

The following indications have been proposed for ketamine: oncological neuropathic pain, post-herpetic neuralgia, chronic trauma, amputation, spinal cord lesion, central origin pain secondary to cerebrovascular accident, phantom limb pain, restless legs syndrome, chronic orofacial pain, fibromyalgia, etc.<sup>40</sup>

Its capacity to reduce neuropathic pain in some studies is reported as superior to opioids, predominantly as an improvement in pain intensity in cancer patients presenting a neuropathic pain component.<sup>41</sup>

The current treatments for central neuropathic pain syndrome are still inadequate. The use of an intravenous infusion of ketamine is a therapeutic alternative. The report suggests that ketamine modulates pain by returning the NMDA receptor to the resting state, whereby the propagation of the pain-inducing signal towards the brain is interrupted, permitting the restoration of the balance between the inhibition and facilitation of pain.<sup>42</sup>

#### **Ketamine as treatment of acute pain in the emergency room**

Intravenous opioids are the main form of management of severe acute pain in the emergency room. Although the opioids deliver rapid and effective pain relief, the doses required to produce suitable analgesia may generate adverse effects such as over-sedation and respiratory depression.<sup>43</sup> Low doses are effective and safe for the treatment of acute pain in emergency rooms, either alone or in combination with opioid analgesics, although their use is associated with greater rates of minor, well-tolerated, adverse side effects.<sup>43,44</sup>

#### **Immunoinhibitory effects**

It is probably the most studied characteristic in recent years, in which immune inhibitory effects have been observed in vitro in the laboratory and in the clinical setting of patients with sepsis; particularly, anti-inflammatories, in modulating innate immunity and pro-inflammatory signalling with down-regulation of the increase in the expression of sepsis-induced TLR2/4.<sup>45–47</sup>

Clinically speaking, ketamine can increase arterial pressure and maintain circulatory stability, mainly as a result of the inhibition of pro-inflammatory cytosine secretion.<sup>48–50</sup> Moreover, it acts upon the metabolism of tryptophan and bioproducts such as kynurenine; a product known to be a modulator of the NMDA receptor functions,<sup>51</sup> and on the production of cortisol.<sup>52</sup>


It could reduce the synthesis of Tumour Necrosis Factor-alpha (TNF- $\alpha$ ) and of Interleukin 6 (IL-6), reducing mitochondrial membrane potential<sup>53,54</sup> by suppressing the production of endotoxin-activated macrophages (LTA) of gram-negative organisms by inhibiting the expression of genes for the production of these two substances.<sup>55</sup> They suppress macrophage function by means of the inhibition of phagocytic activities, oxidative capacity and the synthesis of mRNA (messenger RNA), TNF- $\alpha$  and IL-1b, reducing the activation of nuclear factor (NF)- $\kappa$ B,<sup>56</sup> and the synthesis

**Table 1** Studies in which the use of ketamine for pain was significant.

Author	Year	Surgery	Dose	Time	Results
<i>Single studies</i>					
Jha et al. <sup>77</sup>	2013	Cleft palate repair	0.5 mg/kg infiltration at the surgical site		Lower pain score than with bupivacaine (2 mg/kg) after 24 h, lower rescue analgesia requirement
Eghbal et al. <sup>78</sup>	2013	Adenotonsillectomy	0.25 mg/kg IV bolus		Reduction in emergency reactions, acetaminophen requirement and pain score
Nitta et al. <sup>79</sup>	2013	Spinal, cervical and lower back surgery	2 mg/kg/h IV	Boluses given 5 h perioperative (total 10 mg/kg)	Reduction in the total morphine distributed in 24, 26, 48 and 60 h.
Hadi et al. <sup>80</sup>	2103	Lumbar microdiscectomy	1 mcg/kg/min IV	Peri- and post-operative for a total of 24 h	Reduction in morphine consumption, pain score and PONV
Kim et al. <sup>81</sup>	2013	Lumbar spine fusion	0.5 mg/kg bolus, 2 mcg/kg/min IV infusion	Infusion 48 h post-operative	Lower post-operative fentanyl requirement
Cengiz et al. <sup>82</sup>	2014	Total knee replacement	6 mcg/kg/min IV	Only perioperative	Reduction in morphine consumption after 1, 3, 6, 12 and 24 h, lower pain scores.
Nesher et al. <sup>83</sup>	2008	Thoracic surgery	1 mg morphine, 5 mg IV ketamine		50% reduction in the consumption of morphine after 36 hours, lower pain scores and PONV.
Suppa et al. <sup>84</sup>	2012	Caesarean section	0.5 mg/kg bolus, 2 mcg/kg/min IV infusion	Bolus 10 min post-operative, followed by 12 h infusion	Reduction in sensation of pain in T10 dermatome region.
Zakine et al. <sup>85</sup>	2008	Major abdominal surgery	0.5 mg/kg bolus, 2 mcg/kg/min IV infusion	Perioperative bolus, 48 h infusion	Reduction in morphine consumption, pain score and PONV
de Kock et al. <sup>86</sup>	2001	Rectal adenocarcinoma resection	0.5 mg/kg bolus, 0.25 mcg/kg/h IV infusion	Only perioperative infusion	Lower morphine requirement, fewer hyperalgesia areas and less pain at 6 months follow-up
<i>Systematic reviews and meta-analyses</i>					
Cho et al. <sup>87</sup>	2014	Tonsillectomy	Various	Pre-operative dose	Pain reduction after 4 h, reduction in the need for analgesics after 24 h
Laskowski et al. <sup>88</sup>	2011	Various	Various	Various	100% of the ketamine groups required fewer perioperative opioids, 78% reported less post-operative pain
Elia and Tramer <sup>89</sup>	2005	Various	Various	Various	Reduction in morphine requirement, longer time to use of the first analgesic, less pain at 6 months follow-up.
Subramaniam et al. <sup>90</sup>	2004	Various	Various	Various	Lower single opioid bolus consumption in 64% of the trials, lower continuous opioid infusion consumption in 55% of the trials, beneficial epidural infusion in 63% of the trials
McCartney et al. <sup>91</sup>	2004	Various	0.15–1 mg/kg, several routes	Various	Reduction in post-operative pain and/or lower analgesic consumption in 58% of the trials

PCA, patient-controlled analgesia; PONV, postoperative nausea and vomiting.





**Figure 2** Molecular mechanisms of ketamine that induce down-regulation of the genetic expression of proinflammatory cytokines. AP, activator protein; ERK, extracellular signal-regulated kinase; IKK, inhibitor of nuclear factor kappa-B kinase; IL, interleukin; JNK, c-Jun N-terminal kinase; LBP, lipopolysaccharide binding protein; LPS, lipopolysaccharide; NADPH, nicotinamide adenine dinucleotide phosphate; NF- $\kappa$ B, nuclear factor kappa-B; TLR, toll-like receptor; TNF, tumour necrosis factor.

of IL-6 at transcriptional level, in view of the reduction in the phosphorylation of the ERK1/2 complex mediated by the transduction signal of TLR-2 and TLR-4 and RAGE.<sup>57</sup>

The modification of this signalling pathway is probably one of the multiple ways that down-regulate the activation of nuclear factor NF- $\kappa$ B and the genetic expression of TNF- $\alpha$  and IL-6. Other studies have postulated an impact on critical physiological and psychological functions mediated by the suppression of induction in the activity of nitric oxide synthetase and suppression of the expression of endotoxin-generated proteins.<sup>58</sup> The medicinal product dose-dependently inhibits the inflammatory response induced by lipopolysaccharides (LPS).<sup>59,60</sup> The NMDA receptor also inhibits the extracellular signals regulated by the kinase pathway and the proliferation of carcinomatous cells by cell cycle arrest.<sup>61,62</sup> Another way of inhibiting lymphocyte, NK cell and neutrophil function is by suppressing chemotactic activity, with a reduction in the production of oxidants.<sup>63-65</sup>

Hudenz et al. concluded that single doses of ketamine of 0.5 mg/kg applied during induction were associated with low levels of C-reactive protein (CRP) and a low incidence of delirium and cognitive dysfunction following cardiac surgery performed with extracorporeal circulation pump.<sup>66</sup>

Ketamine induces immune responses in patients that will undergo surgery, since surgical trauma may induce a complex cytokine cascade with different effects on the patient. Some pro-inflammatory cytokines in the immune system are over-stimulated, whereas cell-mediated immunity is suppressed.<sup>67,68</sup> For this reason, certain undesirable effects, such as low blood pressure, shock and multiple organ failure, may occur and compromise patients if the inflammatory response is disproportionate.<sup>69</sup> In view of the known existence of interactions and regulations between pain perception and pro-inflammatory cytokines,<sup>70</sup> it is important to reduce the suppression of lymphocyte-mediated immune response and attenuate the reaction of the pro-inflammatory cytokines to surgery by effective pain management, reducing the response to surgical stress in the post-operative period.<sup>71</sup> Fig. 2 shows the cytokine cascade in which ketamine intervenes during a septic process.

Roytblat et al. also reported that the administration of small doses of ketamine in patients undergoing cardiopulmonary bypass surgery during induction anaesthesia significantly reduced IL-6 serum levels over the 7-day post-operative period,<sup>72</sup> as well as TNF- $\alpha$  and IL-6.<sup>73-75</sup>

Recently, anti-cytokine therapy has been applied to control sepsis using an extracorporeal haemoperfusion device

that specifically absorbs mediators such as the cytokines by means of a neutral micropore resin. Very low levels of IL-6 and IL-8, significant increases in cardiac index, systemic vascular resistance, greater speed in the withdrawal of vasoactive agents, as well as a reduction in heart rate were found in these patients compared to the control group.<sup>75,76</sup>

Although data are limited, particularly in studies in human beings, the existing results call for further and better studies with a greater number of cases exploring the relationship between IL-6 and morbidity and mortality. A greater and continuous effort is called for in order to clarify, in detail, the mechanisms of this suppression in the pro-inflammatory cascade and its influence in the future.

## Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that no patient data appear in this article.

**Right to privacy and informed consent.** The authors declare that no patient data appear in this article.

## Funding

There is no funding.

## Conflict of interests

There are no conflicts of interest.

## References

- Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Cl-581. A new dissociative anesthetic in man. *Clin Pharmacol Ther.* 1965;6:279–91.
- Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity state. *Pain.* 1991;44:293–9.
- Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. *Anesth Analg.* 1998;87:1186–93.
- Idvall J, Aronsen KF, Stenberg P, et al. Pharmacodynamic and pharmacokinetic interactions between ketamine and diazepam. *Eur J Clin Pharmacol.* 2007;24:337–43.
- Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of IM and oral ketamine. *Br J Anaesth.* 1981;53:805–10.
- Clements JA, Nimmo WS. Pharmacokinetics and analgesic effects of ketamine in man. *Br J Anaesth.* 2002;53:27–30.
- Aldrete JA, Paladino MA. *Farmacología para anesestesiólogos, emergentólogos, intensivistas y medicina del dolor.* 1st ed. Buenos Aires: Corpus; 2006. p. 181.
- Smith DJ, Westfall DP, Adams JD. Ketamine interacts with opiate receptors as an agonist. *Anesthesiology.* 1980;53:55.
- Melville NA. Bolus Dose of Ketamine Offers Fast-Acting Alleviation of Acute Depression in ED Setting. Available from: <http://www.medscape.com/viewarticle/729622>.
- López M. Utilización de ketamina en el tratamiento del dolor agudo y crónico. *Rev Soc Esp Dolor.* 2007;1:45–65.
- Mathisen IC, Aasbo V, Raeder J. Lack of pre-emptive analgesic effect of (R)-ketamine in laparoscopic cholecystectomy. *Acta Anaesthesiol Scand.* 2000;43:220–4.
- Scheller M, Bufler J, Hertle I, et al. Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state. *Anesth Analg.* 1996;83:830–6.
- Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. *J Pain Symptom Manag.* 2000;19:S2–6.
- Turk DC, Okifuji A. Pain terms and taxonomies of pain. In: Loeser JD, editor. *Bonica's management of pain.* 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 17.
- Davies SN, Church J, Blake J, et al. Is metaphit a phencyclidine antagonist. *Life Sci.* 1986;30:2441–5.
- Smith DJ, Pekoe GM, Martin LL, et al. The interaction of ketamine with the opiate receptor. *Life Sci.* 1980;26:789–95.
- Finck AD, Samaniego E, Ngai SH. Morphine tolerance decreases the analgesic effects of ketamine in mice. *Anesthesiology.* 1988;68:397–400.
- Aminv P, Roeland E, Atayee R. Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain. *J Pain Palliat Care Pharmacother.* 2014;28:233–42.
- Wsachtel RE. Ketamine decreases the open time of single channel currents activated by acetylcholine. *Anesthesiology.* 1988;68:563–70.
- Rogers R, Wise RG, Painter DJ, et al. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. *Anesthesiology.* 2004;10:292–301.
- Gardner AE, Dannemiller FJ, Dean D. Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia. *Anesth Analg.* 1972;51:741–5.
- Pfenninger E, Ahnefeld FW, Grunert A. Untersuchung zum intrakraniellen dreckverhalten unter ketaminap-likation bei erhaltener spontanatung. *Anesthesist.* 1985;34:191–6.
- Martinez E. Antagonism of ketamine by 4-aminopyridine and physostigmine. *Br J Anaesth.* 1982;54:110.
- Pichlmayr I, Lips U, Kunkel H. The electroencephalogram in anesthesia. Berlin: Springer-Verlag; 1984. p. 102–5.
- Moretti RJ, Hassan SZ, Goodman LI, et al. Comparison of ketamine and thiopental in healthy volunteers: effects on mental status mood, and personality. *Anesth Analg.* 1984;63:1087–96.
- White PF. Pharmacologic interactions of midazolam and ketamine in surgical patients. *Clin Pharmacol Ther.* 1982;31:280.
- Toft P, Romer U. Comparison of midazolam and diazepam to supplement total intravenous anaesthesia with ketamine for endoscopy. *Can J Anaesth.* 1987;34:466–9.
- Reves JG, Flezzani P, Kissin I. Intravenous anesthetic induction drugs. In: Kaplan JA, editor. *Cardiac anesthesia.* New York: Grune and Stratton; 1987. p. 1831–41.
- Murray JP, Lynn AM, Stamm SJ, et al. Hemodynamic effects of ketamine in children with congenital heart disease. *Anesth Analg.* 1984;63:895–9.
- Collins VJ. *Anesthesiología.* McGraw-Hill; 1996.
- Dalrymple NC, Verga M, Anderson KR, et al. The value of unenhanced helical computerized tomography in the management of acute flank pain. *J Urol.* 1998;159:735–40.
- American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. *Anesthesiology.* 2004;100:1573–81.
- Mohamed SA, El-Rahman AMA, Fares KM. Intrathecal dexmedetomidine, ketamine, and their combination added to

- bupivacaine for postoperative analgesia in major abdominal cancer surgery. *Pain Physician*. 2016;19:829–39.
34. Othman AH, El-Rahman AMA, Sherif FAE. Efficacy and safety of ketamine added to local anesthetic in modified pectoral block for management of postoperative pain in patients undergoing modified radical mastectomy. *Pain Physician*. 2016;19:485–94.
  35. Henderson TA. Practical application of the neuroregenerative properties of ketamine: real world treatment experience. *Neural Regen Res*. 2016;11:195–200.
  36. McGuinness SK, Wasiak J, Cleland H, et al. A systematic review of ketamine as an analgesic agent in adult burn injuries. *Pain Med*. 2011;12:1551–8.
  37. Choi E, Lee H, Park HS, et al. Effect of intraoperative infusion of ketamine on remifentanyl-induced hyperalgesia. *Korean J Anesthesiol*. 2015;68:476–80.
  38. Uprety D, Foy BM. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literatura. *Ann Hematol*. 2014;93:769–71.
  39. Neira F, Ortega JL. Antagonistas de los receptores glutamatergicos NMDA en el tratamiento del dolor crónico. *Rev Soc Esp Dolor*. 2004;11:210–22.
  40. Cuesta MJ, Bornay B, Vaquero LM. Ketamina oral: alternativa válida en el tratamiento del dolor facial atípico. A propósito de un caso. *Rev Soc Esp Dolor*. 2003;10:188–90.
  41. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. *Br J Clin Pharmacol*. 2014;77:357–67.
  42. Lo TC, Yeung ST, Lee S, et al. Reduction of central neuropathic pain with ketamine infusion in a patient with Ehlers–Danlos syndrome: a case report. *J Pain Res*. 2016;9:683–7.
  43. Beaudoin FL, Lin C, Guan W, et al. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. *Acad Emerg Med*. 2014;21:1194–202.
  44. Motov S, Rosenbaum S, Vilke GM, et al. Is there a role for intravenous subdissociative-dose ketamine administered as an adjunct to opioids or as a single agent for acute pain management in the emergency department? *J Emerg Med*. 2016;8:1–6.
  45. Park GR, Manara AR, Mendel L, et al. Ketamine infusion. Its use as a sedative, inotrope and bronchodilator in a critically ill patient. *Anaesthesia*. 1987;42:980–3.
  46. Tsao CM, Wu CC. Modulating effects of ketamine on inflammatory response in sepsis. *Acta Anaesth Taiwan*. 2012;50:145–6.
  47. Yu M, Shao D, Liu J, et al. Effects of ketamine on levels of cytokines, NF-kappaB and TLRs in rat intestine during CLP-induced sepsis. *Int Immunopharmacol*. 2007;7:1076–82.
  48. Tsao CM, Wu CC, Wang JJ, et al. Intravenous anesthetics in sepsis. *Acta Anaesthesiol Taiwan*. 2005;43:153–63.
  49. Koga K, Ogata M, Takenaka I, et al. Ketamine suppresses tumor necrosis factor-alpha activity and mortality in carrageenan-sensitized endotoxin shock model. *Circ Shock*. 1994;44:160–8.
  50. Fisar Z, Medina M, Scapagnini G, et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. *Inflammopharmacology*. 2012;20:127–50.
  51. Zunszain MA, Horowitz A, Cattaneo MM, et al. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. *Mol Psychiatry*. 2013;18:1236–41.
  52. Khalili-Mahani N, Martini CH, Olofsen E, et al. Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion. *Br J Anaesth*. 2015;115:68–75.
  53. Persson J. Wherefore ketamine? *Curr Opin Anaesthesiol*. 2010;23:455–60.
  54. Chang Y, Chen TL, Sheu JR, et al. Suppressive effects of ketamine on macrophage functions. *Toxicol Appl Pharmacol*. 2005;204:27–35.
  55. Chang HC, Lin KH, Tai YT, et al. Lipoteichoic acid-induced TNF $\alpha$  and IL-6 gene expressions and oxidative stress production in macrophages are suppressed by ketamine through downregulating toll-like receptor 2-mediated activation of ERK1/2 and NF $\kappa$ B. *Shock*. 2010;33:485–92.
  56. Sun J, Wang XD, Liu H. Ketamine suppresses endotoxin-induced NF-kappaB activation and cytokines production in the intestine. *Acta Anaesthesiol Scand*. 2004;48:317–21.
  57. Chunyan-Yang BD, Yulong-Song MM, Hui-Wang MM. Suppression of RAGE and TLR9 by ketamine contributes to attenuation of lipopolysaccharide-induced acute lung injury. *J Invest Surg*. 2016:1–10.
  58. Yoon SH. Concerns of the anesthesiologist: anesthetic induction in severe sepsis or septic shock patients. *Korean J Anesthesiol*. 2012;63:3–10.
  59. Taniguchi T, Kanakura H, Takemoto Y, et al. Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats. *Tohoku J Exp Med*. 2003;200:85–92.
  60. Taniguchi T, Takemoto Y, Kanakura H, et al. The dose-related effects of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats. *Anesth Analg*. 2003;97:1769–72.
  61. Schmidt H, Ebeling D, Bauer H, et al. Ketamine attenuates endotoxin-induced leukocyte adherence in rat mesenteric venules. *Crit Care Med*. 1995;23:2008–14.
  62. Hirota K, Lambert DG. Ketamine new uses for an old drug? *Br J Anaesth*. 2011;107:123–6.
  63. Suliburk JW, Mercer DW. Ketamine attenuates early lipopolysaccharide induced gastric dysfunction: role of stress-inducible phosphoproteins. *J Trauma*. 2007;62:316–9.
  64. Weigand MA, Schmidt H, Zhao Q, et al. Ketamine modulates the stimulated adhesion molecule expression on human neutrophils in vitro. *Anesth Analg*. 2000;90:206–12.
  65. Zahler S, Heindl B, Becker BF. Ketamine does not inhibit inflammatory responses of cultured human endothelial cells but reduces chemotactic activation of neutrophils. *Acta Anaesthesiol Scand*. 1999;43:1011–6.
  66. Hudetz JA, Patterson KM, Iqbal Z, et al. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth*. 2009;23:651–7.
  67. Ni Choileain N, Redmond HP. Cell response to surgery. *Arch Surg*. 2006;141:1132–40.
  68. Zilberstein G, Levy R, Rachinsky M, et al. Ketamine attenuates neutrophil activation after cardiopulmonary bypass. *Anesth Analg*. 2005;95:531–6.
  69. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. *Chest*. 1991;112, 321S–7S.
  70. Watkins LR, Mair SF, Goehler LE. Immune activation: the role of proinflammatory cytokines in inflammation, illness responses, and pathological pain states. *Pain*. 1995;63:289–302.
  71. Beilin B, Shavit Y, Trabekín E, et al. The effects of postoperative pain management on immune response to surgery. *Anesth Analg*. 2003;97:822–7.
  72. Roytblat L, Talmor D, Rachinsky M, et al. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. *Anesth Analg*. 1998;87:266–71.
  73. Huang Z, Wang SR, Su W, et al. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. *Ther Apher Dial*. 2010;14:596–602.
  74. Roussabrov E, Davies JM, Bessler H, et al. Effect of ketamine on inflammatory and immune responses after short duration surgery in obese patients. *Open Anesthesiol J*. 2008;2:40–5.



75. Lu HW, He GN, Ma H, et al. Ketamine reduces inducible superoxide generation in human neutrophils in vitro by modulating the p38 mitogenactivated protein kinase (MAPK)-mediated pathway. *Clin Exp Immunol.* 2010;160:450–6.
76. Song XM, Li JG, Wang YL, et al. Effects of ketamine on proinflammatory cytokines and nuclear factor kappa B in polymicrobial sepsis rats. *World J Gastroenterol.* 2006;12:7350–4.
77. Jha AK, Bhardwaj N, Yaddanapudi S, et al. A randomized study of surgical site infiltration with bupivacaine or ketamine for pain relief in children following cleft palate repair. *Paediatr Anaesth.* 2013;23:401–6.
78. Eghbal MH, Taregh S, Amin A, et al. Ketamine improves postoperative pain and emergence agitation following adeno-tonsillectomy in children. A randomized clinical trial. *Middle East J Anesthesiol.* 2013;22:155–60.
79. Nitta R, Goyagi T, Nishikawa T. Combination of oral clonidine and intravenous low-dose ketamine reduces the consumption of postoperative patient-controlled analgesia morphine after spine surgery. *Acta Anaesthesiol Taiwan.* 2013;51:14–7.
80. Hadi BA, Daas R, Zelk'o R. A randomized, controlled trial of a clinical pharmacist intervention in microdiscectomy surgery—low dose intravenous ketamine as an adjunct to standard therapy. *Saudi Pharm J.* 2013;21:169–75.
81. Kim SH, Kim SI, Ok SH, et al. Opioid sparing effect of low dose ketamine in patients with intravenous patient-controlled analgesia using fentanyl after lumbar spinal fusion surgery. *Korean J Anesthesiol.* 2013;64:524–8.
82. Cengiz P, Gokcinar D, Karabeyoglu I, et al. Intraoperative low-dose ketamine infusion reduces acute postoperative pain following total knee replacement surgery: a prospective, randomized double-blind placebo-controlled trial. *J Coll Physicians Surg—Pakistan.* 2014;24:299–303.
83. Neshar N, Serovian I, Marouani N, et al. Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. *Pharmacol Res.* 2008;58:38–44.
84. Suppa E, Valente A, Catarci S, et al. A study of low-dose S-ketamine infusion as 'preventive' pain treatment for cesarean section with spinal anesthesia: benefits and side effects. *Minerva Anesthesiol.* 2012;78:774–81.
85. Zakine J, Samarcq D, Lorne E, et al. Postoperative ketamine administration decreases morphine consumption in major abdominal surgery: a prospective, randomized, double-blind, controlled study. *Anesth Analg.* 2008;106:1856–61.
86. de Kock M, Lavand'homme P, Waterloos H. 'Balanced analgesia' in the perioperative period: is there a place for ketamine? *Pain.* 2001;92:373–80.
87. Cho HK, Kim KW, Jeong YM, et al. Efficacy of ketamine in improving pain after tonsillectomy in children: meta-analysis. *PLOS ONE.* 2014;9. Article ID e101259.
88. Laskowski K, Stirling A, McKay WP, et al. A systematic review of intravenous ketamine for postoperative analgesia. *Can J Anesth.* 2011;58:911–23.
89. Elia N, Tramer MR. Ketamine and postoperative pain—a quantitative systematic review of randomised trials. *Pain.* 2005;113(1-2):61–70.
90. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. *Anesth Analg.* 2004;99:482–95.
91. McCartney CJL, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. *Anesth Analg.* 2004;98:1385–400.